Affiliation:
1. Department of Laboratory Medicine Chungbuk National University Hospital Cheongju‐si Korea
2. Department of Laboratory Medicine Chungbuk National University College of Medicine Cheongju‐si Korea
3. Institute of Reproductive Medicine and Population Medical Research Center Seoul National University Seoul Korea
4. School of Health and Environmental Science, College of Health Science Korea University Seoul Korea
5. Department of Internal Medicine Seoul National University Hospital Seoul Korea
6. Department of Internal Medicine Seoul National University College of Medicine Seoul Korea
7. Department of Electrical and Computer Engineering Seoul National University Seoul Korea
8. Bio‐MAX Institute Seoul National University Seoul Korea
9. BK21 FOUR R&E Center for Learning Health Systems Korea University Seoul Korea
10. Department of Laboratory Medicine Seoul National University College of Medicine Seoul Korea
Abstract
AbstractIntroductionRecently, multigene target sequencing is widely performed for the purpose of prognostic prediction and application of targeted therapy. Here, we proposed a new scoring system that encompasses gene variations, telomere length, and Revised International Prognostic Scoring System (IPSS‐R) together in Asian myelodysplastic syndrome.MethodsWe developed a new scoring model of these variables: age ≥ 65 years + IPSS‐R score + ASXL1 mutation + TP53 mutation + Telomere length (<5.37). According to this new scoring system, patients were divided into four groups: very good score cutoff (≤3.0), good (3.0–4.5), poor (4.5–7.0), and very poor (>7.0).ResultsThe median OS was 170.1, 100.4, 46.0, and 12.0 months for very good, good, poor, and very poor, retrospectively (p < 0.001). Meanwhile, according to the conventional IPSS‐R scoring system, the median OS was 141.3, 50.2, 93.0, 36.0, and 16.2 months for very low, low, intermediate, high, and very high, retrospectively (p < 0.001).ConclusionsThe newly developed model incorporating molecular variations and TL yielded more clear separations of the survival curves. By adding the presence of gene mutation and telomere length to the existing IPSS‐R, its predictive ability can be further improved in myelodysplastic syndrome.
Funder
National Research Foundation of Korea
Ministry of Science and ICT, South Korea
Subject
Microbiology (medical),Biochemistry (medical),Medical Laboratory Technology,Clinical Biochemistry,Public Health, Environmental and Occupational Health,Hematology,Immunology and Allergy